Teva Pharmaceutical Industries (TEVA) Q2 FY2026 earnings: revenue $4.1 billion, down 0.8% on the year
Teva Pharmaceutical Industries Ltd. (TEVA) reported revenue of $4.1 billion for Q2 FY2026, the quarter ended 30 June 2026, down 0.8% on the same quarter a year earlier. Net income was -$576 million, and diluted earnings per share $-0.49. The figures are the company's own, from the 10-Q it filed with the SEC on 29 July 2026.
Revenue
$4.1 billion
-0.8% on the year · +4.0% on the quarter
Q3 FY2024Q2 FY2026
Operating margin
-5.6%
10.9% a year earlier
Q3 FY2024Q2 FY2026
Net income
-$576 million
Q3 FY2024Q2 FY2026
Diluted EPS
-$0.49
Q3 FY2024Q2 FY2026
this quarterthe same quarter a year earlierHover a bar for its figure.
What management said
Guidance figures: 1 raised, 2 new, 9 kept.
Revenue slightly lower, innovative brands grew: Q2 revenues were $4.1 billion, down 1% in US dollars and 3% in local currency, mainly from lower lenalidomide capsule revenue. AUSTEDO, AJOVY and UZEDY together grew 43% in local currency to over $1 billion.
Non-GAAP EPS fell on Emalex charge: GAAP loss per share was $0.49. Non-GAAP diluted EPS was $0.02, including a ($0.61) per share impact from the Emalex acquisition expenses.
US segment loss on ecopipam R&D: US segment revenue was $1,702 million, down 5%. Segment profit was a loss of $76 million, mainly from R&D of $883 million tied to the Emalex acquisition.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
Q2 FY2026
Q1 FY2026
Q2 FY2025
On the quarter
On the year
Last 8 quarters
Operating cash flow
411
-40.0
227
+81.1%
Capital expenditure
104
168
96.0
-38.1%
+8.3%
Free cash flow
307
-208
131
+134.4%
Free cash flow margin
7.4%
-5.2%
3.1%
Cash from investing
-491
229
236
Cash from financing
-1.0
13.0
6.0
Depreciation and amortisation
241
239
251
+0.8%
-4.0%
Share-based compensation
40.0
43.0
38.0
-7.0%
+5.3%
Diluted shares, weighted
1,165m
1,179m
1,161m
-1.2%
+0.3%
Shares outstanding at period end
1,165m
1,164m
1,147m
+0.1%
+1.6%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q2 FY2026
Q1 FY2026
Q2 FY2025
On the quarter
On the year
Last 8 quarters
Shareholders' equity
7,753
8,228
6,827
-5.8%
+13.6%
Non-controlling interest
4.0
4.0
7.0
0.0%
-42.9%
Redeemable equity
n/a
n/a
0.0
Debt
16,592
16,627
17,227
-0.2%
-3.7%
Operating lease liabilities
282
280
296
+0.7%
-4.7%
Other liabilities
15,226
14,901
15,774
+2.2%
-3.5%
Total liabilities and equity
39,857
40,040
40,131
-0.5%
-0.7%
Fixed assets
3,928
3,998
4,810
-1.8%
-18.3%
Goodwill
15,839
15,822
15,949
+0.1%
-0.7%
Intangible assets
3,447
3,609
4,142
-4.5%
-16.8%
Cash and equivalents
3,655
3,741
2,161
-2.3%
+69.1%
Receivables
3,493
3,393
3,564
+2.9%
-2.0%
Inventory
3,221
3,176
3,497
+1.4%
-7.9%
Other assets
6,274
6,301
6,008
-0.4%
+4.4%
Total assets
39,857
40,040
40,131
-0.5%
-0.7%
Questions
What was Teva Pharmaceutical Industries' revenue in Q2 FY2026?
Teva Pharmaceutical Industries (TEVA) reported revenue of $4.1 billion for Q2 FY2026, the quarter ended 30 June 2026, down 0.8% on the same quarter a year earlier.
How much did Teva Pharmaceutical Industries earn in Q2 FY2026?
Net loss for Q2 FY2026 was $576 million, and the diluted loss per share $0.49.
When did Teva Pharmaceutical Industries report Q2 FY2026 results?
Teva Pharmaceutical Industries filed its 10-Q for the quarter ended 30 June 2026 with the SEC on 29 July 2026.
Each quarter as filed, linked to its filing. Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-Q for the period ended 30 June 2026, filed 29 July 2026: the filing.